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Background and purpose   Factors that lead to periprosthetic 
bone loss following total hip arthroplasty (THA) may not only 
depend  on  biomechanical  implant-related  factors,  but  also  on 
various patient-related factors. We investigated the association 
between  early  changes  in  periprosthetic  bone  mineral  density 
(BMD) and patient-related factors. 
Patients and methods   39 female patients underwent cement-
less THA (ABG II) with ceramic-ceramic bearing surfaces. Peri-
prosthetic BMD in the proximal femur was determined with DXA 
after surgery and at 3, 6, 12, and 24 months. 27 patient-related 
factors were analyzed for their value in prediction of peripros-
thetic bone loss. 
Results   Total periprosthetic BMD was temporarily reduced 
by 3.7% at 3 months (p < 0.001), by 3.8% at 6 months (p < 0.01), 
and by 2.6% at 12 months (p < 0.01), but recovered thereafter up 
to 24 months. Preoperative systemic osteopenia and osteoporosis, 
but not the local BMD of the operated hip, was predictive of bone 
loss in Gruen zone 7 (p = 0.04), which was the only region with a 
statistically significant decrease in BMD (23%, p < 0.001) at 24 
months. Preoperative serum markers of bone turnover predicted 
the early temporary changes of periprosthetic BMD. The other 
patient-related factors failed to show any association with the 
periprosthetic BMD changes. 
Interpretation   Female patients with low systemic BMD show 
greater bone loss in Gruen zone 7 after cementless THA than 
patients with normal BMD. Systemic DXA screening for osteo-
porosis in postmenopausal patients before THA could be used to 
identify patients in need of prophylactic anti-resorptive therapy.

Stress-shielding seems to be the most important single factor 
causing  bone  loss  in  the  femur  after  cementless  total  hip 
arthroplasty (THA) (Tanzer et al. 2001, Sköldenberg et al. 
2006). However, various patient-related factors may also be 
involved (Venesmaa et al. 2001, Aldinger et al. 2003). Some 
studies have suggested that the rate of bone turnover deter-
mined by metabolic bone markers (Yamaguchi et al. 2003) 
and systemic bone mineral density (BMD) measured from 
the lumbar spine, contralateral hip and forearm (Rahmy et al. 
2004, Grochola et al. 2008, van der Wal et al. 2008) can pre-
dict periprosthetic bone loss. The process is believed to carry 
a risk of implant failure and difficulty with the performance 
of a revision surgery (Haddad et al. 1999). Thus, it may be an 
indication for preventive anti-resorptive therapy (Bhandari et 
al. 2005). 
Undiagnosed  osteoporosis  is  surprisingly  common  in 
patients with hip osteoarthritis (OA) (Glowacki et al. 2003). 
A recent study from our group also showed a high rate of pri-
mary and secondary osteoporosis in females with advanced 
OA of the hip (Mäkinen et al. 2007). These patients have now 
undergone cementless THA and we have evaluated them pro-
spectively for the influence of various patient-related factors 
on periprosthetic bone remodeling in the proximal femur. 
Patients and methods
Inclusion and exclusion criteria
The  original  patient  population  consisted  of  61  consecu-
tive osteoarthritic women undergoing THA surgery between 
August 2003 and March 2005. The Ethics Committee of the 
Hospital District of Southwest Finland approved the study 
protocol (16.04.2002, # 4/2002§76). Informed consent was 
obtained from all patients. The exclusion criteria applied were: 
Paget’s disease, disorder of parathyroid function, and/or treat-
ment with corticosteroids, bisphosphonates, or calcitonin. 8 
patients were excluded due to previously diagnosed osteopo-
rosis or systemic corticosteroid use. 10 patients were excluded 
because of severe osteoporosis (T-score < –3.5 at any anatomi-
cal location) requiring the initiation of anti-resorptive therapy. 
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could not complete the study protocol due to surgical compli-
cations (periprosthetic fracture) and 2 patients were excluded 
from the analysis because of omission of baseline DXA mea-
surements. Thus, 39 patients were enrolled (Table 1). The Z-
scores showed a high variance. Still, the mean Z-scores were 
relatively high (1.16–1.33), indicating that the study cohort 
was representative of OA patients with a trend of having BMD 
in the upper scale of the normal range (Dequeker et al. 2003). 
Preoperative evaluation
To assess functional disability, the patients were evaluated with 
the Harris hip score and the Western Ontario and McMaster 
Universities osteoarthritis index (WOMAC). 
Radiographic OA was classified by 2 independent observers 
using the Kellgren-Lawrence grading system. The shape and 
the bone quality of the proximal femur were assessed by the 
qualitative classification into 3 distinct pattern types (Dorr type 
A, B, or C). The canal flare index (CFI) was calculated from 
digital radiographs (Noble et al. 1998). Briefly, the metaphy-
seal width 20 mm proximal to the most prominent point of the 
lesser trochanter (D) and the intramedullary femoral isthmus 
width (G) were measured. CFI was calculated as the ratio of 
D to G, and the canal shapes of the femurs were classified as 
normal (3-4.7), stovepipe (< 3), or champagne-flute (> 4.7) 
(Table 1). These parameters were statistically tested as radio-
graphic predictors of periprosthetic bone loss. 
Standard laboratory tests were done in order to detect meta-
bolic bone disorders and vitamin D insufficiency, as described 
previously (Mäkinen et al. 2007). Complete blood cell count, 
plasma calcium (P-Ca), serum ionized calcium (S-Ca-Ion), 
plasma  phosphorus  (P-Pi),  serum  parathyroid  hormone  (S-
PTH),  and  25-hydroxyvitamin  D  (S-25(OH)D)  were  mea-
sured. Biochemical markers of bone turnover were determined 
in order to evaluate the rate of bone formation and resorp-
tion as predictors of periprosthetic bone loss. 3 biochemical 
serum markers—osteocalcin (OC), bone alkaline phosphatase 
(bone ALP), and intact procollagen type I N propeptide (intact 
PINP)—were used to assess the rate of bone formation. To 
evaluate the rate of bone resorption, serum levels of C-termi-
nal crosslinking telopeptide of type I collagen (CTX), N-ter-
minal crosslinking telopeptide of type I collagen (NTX), and 
tartrate-resistant acid phosphatase type 5b (TRACP 5b) were 
assayed as described previously (Mäkinen et al. 2007). 
DXA measurements
Bone mineral density (BMD) was measured with a Hologic 
QDR 4500C densitometer (Hologic Inc., Waltham, MA) at 
the lumbar spine (from L1 to L4), proximal femurs, and distal 
non-dominant forearm. Based on the DXA results, the patients 
were  divided  into  3  groups:  normal  BMD,  osteopenia,  or 
osteoporosis (Table 1). A patient was classified as osteopenic 
if she had a T-score of between –1 and –2.5 in any of the afore-
mentioned densitometry sites. Correspondingly, a patient with 
a T-score of less than –2.5 was classified as osteoporotic. 
DXA measurement of periprosthetic BMD was performed 
within 7 days of surgery (baseline) and the measurement was 
repeated at 3, 6, 12, and 24 months. During successive DXA 
scans,  the  patient’s  leg  was  positioned  in  a  standard  neu-
tral rotation using a supporting device. Data were analyzed 
using software provided by the manufacturer (Metal Removal 
Option, Hologic). Periprosthetic BMD in the proximal femur 
was determined from 7 regions of interest (ROIs) (Figure 1) 
based on Gruen zones. BMD data of zones 1 through 7 were 
also combined to form a total periprosthetic BMD. The preci-
Figure 1. Gruen zones used in DXA 
analysis of periprosthetic BMD. 
Table 1. Demographic data, preoperative DXA, and radiographic findings
Patient characteristics    DXA and radiography 
Age (years)    63 (41–79)   Z-scores 
Height (cm)   162 (SD 6)      Lumbar spine (L1-L4 total)   1.33 (SD 1.24)
Weight (kg)     81 (SD 17)      Contralateral hip (total)   1.17 (SD 0.92)
BMI     31 (SD 6.3)      OA hip (total)     1.16 (SD 0.98)
Previous fractures (n)     10      Non-dominant forearm    1.19 (SD 0.86)
Postmenopausal (n)     36   Systemic BMD (T-scores) 
S-25(OH)D < 50 nmol/L (n)     15      Normal BMD (n)     12 
Smokers (n)       4      Osteopenia (n)     22 
Alcohol consumption:         Osteoporosis (n)     5 
   1–5 drinks/week     13   Kellgren-Lawrence score: 
   6–10 drinks/week       7        2 (n)     3 
WOMAC score     51 (SD 16)      3 (n)     17 
Harris hip score     49 (SD 15)      4 (n)     19 
       Canal flare index: 
          Stovepipe (n)     4 
          Normal (n)     31 
          Champagne-Flute (n)     4
        Dorr classification: 
          Type A (n)     22 
          Type B (n)     16 
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sion error of the Hologic DXA system was measured in 59 
double scans performed at different follow-up time points. 
The precision error varied from 1.5% to 3.4% depending on 
the ROIs, with an average precision error of 2.3%, which is 
comparable to other studies (Venesmaa et al. 2001).
Surgery
The patients underwent cementless THA (Anatomic Benoist 
Girard II, ABG II, Stryker). The shape of the femoral stem of 
the prosthesis is meant to follow the anatomical contours of 
the proximal femur in all 3 dimensions, in order to ensure that 
the load transfer pattern imitates (as closely as possible) the 
natural distribution of bone stress within physiological limits 
(van Rietbergen and Huiskes 2001). The stem is made of tita-
nium alloy with a low modulus (TMZF, 85 GPa) and has a 
proximal hydroxyapatite (HA) coating. The distal part of the 
stem has been made short and undersized, and its surface has 
been ultrapolished to avoid distal bonding. The stem sizes used 
were 3 (17 patients), 4 (9 patients), and 5 (13 patients). Thus, 
the average stem size was 4.6. The cementless press-fit cups 
were also HA-coated. Ceramic heads (28 mm) and ceramic 
liners (both made of aluminium oxide ceramic, Al2O3) were 
used. The patients were operated according to standard tech-
niques using an anterolateral Hardinge approach. According 
to the prevailing clinical practice, the patients were instructed 
to perform partial weight bearing; this was followed by full 
weight bearing after 6 weeks. 
Statistics
The  main  variable  investigated,  the  time-related  change  in 
BMD in the periprosthetic regions, was analyzed using analy-
sis of variance for repeated measurements with Bonferroni’s 
correction for multiple comparisons between the time points. 
The  statistical  significance  of  preoperative  patient-related 
factors  for  prediction  of  time-related  periprosthetic  BMD 
changes was evaluated using analysis of variance for repeated 
measurements (categorical factors) and analysis of covariance 
for repeated measurements (continuous factors) with Tukey’s 
adjustment for multiple comparisons. The significance of each 
patient-related factor for the observed changes in BMD at the 
endpoint was determined using linear models with calculation 
of the coefficients of determination (R2) for these models. Con-
tinuous variables were treated as covariates, while categorical 
variables were treated as fixed factors with Tukey’s adjustment 
for multiple comparisons when comparing the categories. The 
demographic patient-related factors investigated included age, 
body mass index, serum vitamin D level, previous fractures, 
alcohol consumption, and preoperative WOMAC and Harris 
hip scores. Also, the radiological parameters CFI, Dorr clas-
sification  and  Kellgren-Lawrence  scores  were  analyzed  for 
their value as predictors of periprosthetic BMD changes. When 
investigating the association between the rate of bone turnover 
and changes in periprosthetic BMD, biochemical serum mark-
ers were analyzed by quartiles with the two middle quartiles 
combined (lowest 25%, middle 50%, and highest 25%). In addi-
tion, the uncoupling index was calculated in order to evaluate 
the balance of bone turnover, taking into account all 6 markers 
of bone formation and resorption (Eastell et al. 1993). 
The association between preoperative BMD and peripros-
thetic bone loss in the femur was investigated using both the 
local BMD of the operated hip and the systemic BMD (based 
on the lowest T-scores). 
Differences in absolute BMD of Gruen zone 7 between the 3 
patient groups (normal BMD, osteopenia, osteoporosis) were 
analyzed at baseline and at 24 months using one-way analy-
ses of variance with Tukey’s adjustment for multiple compari-
sons. 
For Gruen zone 7, the association between baseline BMD 
and absolute loss in BMD (g/cm2) as well as the association 
between change in BMD (%) and the lowest preoperative sys-
temic T-score were analyzed with linear regression and pre-
sented with the coefficient of determination (R2).
Statistical  analyses  were  done  using  SAS  software  for 
Windows, release 9.1 (SAS Institute Inc., Cary, NC). Linear 
regression was done using SPSS version 16.0 for Windows. P-
values less than 0.05 were considered statistically significant.
Results
Clinical outcome
All 39 patients completed the study protocol with sequential 
clinical and radiographic evaluation and periprosthetic DXA 
measurements up to 24 months. None of them showed radio-
graphic signs of component loosening or periprosthetic oste-
olysis. The functional outcome of the THA evaluated with 
Harris hip score improved from an average preoperative score 
of 49 (13–75) points to 84 (47–100) points at 24 months. The 
WOMAC score also improved from 51 (33–95) points to 15 
(0–59) after surgery. 
Periprosthetic BMD changes 
Gruen zones 1, 2, and 3 showed transient decrease in BMD 
during the first 6 months after THA but recovered thereaf-
ter  (Table  2). Total  periprosthetic  BMD  became  temporar-
ily reduced by 3.7% at 3 months (p < 0.001), by 3.8% at 6 
months (p < 0.01), and by 2.6% at 12 months (p < 0.01), but 
it approached the baseline value by 24 months (Table 2). At 
24 months, 2 zones showed a statistically significant change 
in BMD compared to baseline: Gruen zone 5 with a 5.2% 
increase (p < 0.001) and Gruen zone 7 with a 23% decrease 
(p < 0.001). Radiographs showed cortical bone rounding in 
Gruen zone 7 (Figure 2) as a sign of adaptive remodeling. 
Patient-related factors in periprosthetic bone remod-
eling
The preoperative systemic BMD, evaluated from 3 anatomi-
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non-dominant forearm), predicted bone loss in Gruen zone 7 
(p = 0.04). Patients with osteopenia or osteoporosis showed a 
greater bone loss in Gruen zone 7 than patients with normal 
systemic BMD (Figure 3). At 24 months, patients with normal 
systemic BMD showed higher BMD in Gruen zone 7 than 
osteopenic and osteoporotic patients (p = 0.006 and p = 0.01, 
respectively). Regression analysis (Figure 4) confirmed that 
low preoperative systemic BMD was associated with higher 
bone loss in Gruen zone 7 (R2 = 0.15, R = 0.38, p = 0.02). The 
local BMD (preoperative total BMD of the operated femur) did 
not act as an independent predictor of periprosthetic bone loss 
in Gruen zone 7. In Gruen zone 7, no association was found 
between the baseline BMD and loss of BMD at 24 months. 
High preoperative levels of the resorption marker NTX were 
predictive of bone loss at 3 and 6 months (p < 0.001 and p 
= 0.001, respectively) in Gruen zone 2. TRACP-5b, another 
Table 2. Mean BMD of periprosthetic bone and percentage change during follow-up, with 95% confidence intervals
Gruen  BMD (g/cm2)  Percentage change from baseline
zones  Baseline   3 months   6 months   12 months   24 months   3 months   6 months   12 months   24 months
1  mean   0.71   0.68  0.68  0.67  0.67  –2.5 a   –2.9  –3.7  –3.1
    95% CI  0.66–0.75  0.64–0.72  0.64–0.72   0.63–0.71  0.63–0.71  –5.6 to 0.67  –7.4 to 1.7  –9.2 to 1.9  –8.4 to 2.3
2  mean  1.29   1.22  1.22  1.24  1.25  –5.5 b  –5.8 c  –3.5  –2.6
    95% CI  1.24–1.35  1.16–1.28  1.16–1.27  1.19–1.29  1.20–1.30  –8.3 to –2.6   –8.2 to –3.3  –6.4 to –0.6  –6.0 to 0.8
3  mean  1.53  1.48  1.48  1.50  1.53  –3.5 a  –3.0 a  –1.9    0.7
    95% CI  1.49–1.57  1.42–1.53  1.43–1.53  1.45–1.55  1.48–1.59  –5.9 to –1.1  –5.1 to –0.9  –4.1 to 0.4  –1.9 to 3.3
4  mean  1.67   1.65  1.65  1.67  1.69  –1.5  –1.1    0.1    1.1
    95% CI  1.62–1.73  1.58–1.71  1.60–1.71  1.62–1.73  1.63–1.75  –2.9 to –0.2  –2.3 to 0.1  –0.9 to 3.0  –1.5 to 1.6
5  mean   1.55  1.56  1.59  1.61  1.63    0.8    2.2 a    3.5 c    5.2 c
    95% CI  1.50–1.60  1.51–1.62  1.54–1.63  1.56–1.65  1.59–1.68  –1.2 to 2.7    0.74–3.7    1.9 –5.0    3.1–7.3
6  mean   1.31  1.27  1.26  1.29  1.31  –3.1  –3.5  –1.3  –0.7
    95% CI  1.24–1.37  1.20–1.33  1.19–1.32  1.22–1.36  1.24–1.38  –5.7 to –0.4  –6.5 to –0.6  –4.6 to 1.9  –4.2 to 2.8
7  mean   1.12  0.93  0.88  0.88  0.87  –16 c  –21 c  –21 c  –23 b
    95% CI  1.04–1.19  0.86–1.0  0.80–0.96  0.80–0.96  0.79–0.96  –20 to –13   –25 to –17  –26 to –17   –28 to –18
Total BMD  1.23  1.18  1.18  1.19  1.21  –3.7 c  –3.8 b  –2.6 b  –1.5
    95% CI  1.19–1.27  1.14–1.22   1.14–1.22   1.16–1.23  1.17–1.25  –5.2 to –2.2  –5.2 to –2.5  –4.3 to –1.0  –3.4 to 0.4
a p<0.05, b p<0.01, c p<0.001, p-values with Bonferroni corrections: significant changes in BMD compared to baseline values. 
Figure 2. An ABG II hip prosthesis postoperatively (a) and at 24 months (b). Bone 
loss in Gruen zone 7 was seen as rounding off of the medial femoral neck (shown 
with circle). 
Figure 3. Change in BMD in Gruen zone 7 in THA patients 
with normal or low systemic BMD, as a function of heal-
ing time. In all groups, bone loss in this zone was statisti-
cally significant at 24 months (p < 0.001). Osteopenic (n 
= 22) and osteoporotic (n = 5) patients showed greater 
bone loss than patients with normal BMD (n = 12) (p = 
0.037). Mean values and 95% CIs are given.
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resorption marker, was also associated with bone loss in the 
same zone at 3 months (p < 0.001) and a low level of bone 
formation marker intact PINP was predictive of the transient 
bone loss in Gruen zone 2 (p = 0.01) at 6 months. Uncou-
pling index also predicted changes in BMD in Gruen zone 2 
(p = 0.002). Patients with positive index (turnover in favor of 
bone formation) showed better preservation of periprosthetic 
bone than those with negative index (turnover in favor of bone 
resorption). High preoperative serum bone ALP predicted the 
continuous increase in BMD (p = 0.04) in Gruen zone 5. 
None of the radiographic parameters of the proximal femur 
morphology (Table 1) predicted periprosthetic bone loss. The 
percentage decrease in the total periprosthetic BMD at 3 and 
6 months was greater in patients with baseline alcohol intake 
of 6–10 drinks per week than in non-users (p = 0.01), but at 12 
and 24 months there were no differences in the absolute BMD 
values between alcohol users and non-users. 
Discussion
Unexpectedly,  this  study  showed  a  statistically  significant 
decrease in total periprosthetic BMD only during the first 12 
months. At 24 months, only Gruen zone 7 showed statisti-
cally significant bone loss. Low systemic BMD (osteopenia 
or osteoporosis) predicted this local adverse remodeling pro-
cess. Interestingly, both the local preoperative BMD of the 
operated hip and the baseline BMD of Gruen zone 7 failed 
to act as independent predictors of the process, most likely 
due to the secondary changes in BMD in the femoral neck 
and trochanteric region caused by the underlying OA of the 
hip (Mäkinen et al. 2007). Probably due to the same process, 
fragility fracture of an OA hip is extremely rare and DXA of 
the affected hip may give falsely high BMD values for evalu-
ation of systemic osteoporosis, resembling artefacts caused by 
lumbar spine degeneration. 
Total periprosthetic BMD of the proximal femur has been 
shown to decrease by 5–10% within 2 years after cementless 
THA (Tanzer et al. 2001, Venesmaa et al. 2001, Kärrholm et 
al. 2002, Aldinger et al. 2003, Rahmy et al. 2004, Grant et al. 
2005, Sköldenberg et al. 2006, van der Wal et al. 2008) with 
a slow progressive loss or minimal recovery during the fol-
lowing years (Aldinger et al. 2003). Our study demonstrated 
only temporary loss of total periprosthetic BMD during the 
first 12 months, followed by recovery thereafter. The mainte-
nance of the periprosthetic bone probably reflects the mechan-
ical characteristics of the femoral stem, confirming the idea 
that implant-related factors are most critical for preservation 
of bone stock (van Rietbergen and Huiskes 2001). Previous 
studies using the same prosthesis have shown a 4.1% decrease 
in total periprosthetic BMD at 24 months (van der Wal et al. 
2006). Several factors could explain our favorable results. The 
averaged stem size was somewhat larger than in previous stud-
ies (van der Wal et al. 2006, 2008). A larger stem size in itself 
can increase periprosthetic bone loss (Sköldenberg et al. 2006) 
but, on the other hand, stability can be improved by larger 
stems, thus eliminating distal bone loss seen with smaller ABG 
II stems (van der Wal et al. 2006). A larger stem may also help 
to avoid malalignment of the stem, which appears to cause 
periprosthetic bone loss in ABG II arthroplasties (Panisello et 
al. 2006). 
The major decrease in periprosthetic BMD in Gruen zone 7 
is a common finding in cementless THAs (Tanzer et al. 2001, 
Venesmaa et al. 2001, Aldinger et al. 2003, Yamaguchi et al. 
2003, Rahmy et al. 2004, Sköldenberg et al. 2006, van der 
Wal et al. 2008). The periprosthetic changes in BMD for the 
cemented stems follow the pattern observed in cementless 
THAs, with the highest bone loss in Gruen zone 7 (Li et al. 
2007). In patients with cemented THAs, low systemic BMD 
and high bone loss in Gruen zones 7 and 1 have been found 
to be predictive of late stem loosening (Nixon et al. 2007), 
but no association between periprosthetic bone loss and stem 
migration has been shown, as evaluated by RSA (Li et al. 
2007). Regarding cementless THA, the long-term effect of 
periprosthetic bone loss is unclear. This might be a concern, 
as the contemporary cementless THAs are expected to survive 
for 30–40 years in middle-aged patients and an increasing 
number of cementless THAs are being performed in osteo-
porotic postmenopausal women with an increased life expec-
tancy. Thus, every effort should be made to minimize the loss 
of periprosthetic bone stock. In a sheep model of cemented 
hemiarthroplasty, intravenous administration of long-lasting 
zoledronic acid was found to reduce cortical osteopenia in 
Figure 4. Linear regression (with 95% confidence intervals) demon-
strating the association (R2 = 0.147, R = 0.38, p = 0.015) between 
preoperative systemic BMD (lowest preoperative T-score) and change 
in periprosthetic femur BMD (in Gruen zone 7) at 24 months after THA 
(n = 36). 
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Gruen zone 7 (Goodship et al. 2008). Also, several human 
studies have indicated the efficacy of other bisphosphonates 
in prevention of periprosthetic bone loss (Wilkinson et al. 
2001,  Bhandari  et  al.  2005).  Extending  previous  observa-
tions (Rahmy et al. 2004, van der Wal et al. 2008, Grochola 
et al. 2008), the current study demonstrated higher peripros-
thetic bone loss in Gruen zone 7 in patients with low systemic 
BMD. These patients may represent an ideal target group of 
THA patients for definitive clinical trials of prophylactic anti-
resorptive therapy. 
In previous studies, determination of metabolic bone mark-
ers has given different results in terms of their reliability for 
monitoring periprosthetic bone loss (Wilkinson et al. 2001, 
Yamaguchi et al. 2003, Habermann et al. 2007). In our study, 
4 markers and the uncoupling index were able to detect the 
rapid transient BMD changes in 2 Gruen zones during the 
first 3-6 months. Such a high turnover of periprosthetic bone 
represents the healing process of cementless THAs, which is 
known to mimic fracture healing. 
The strength of our study was characterized by 4 factors: 
(1) the inclusion of a homogenous patient population of the 
same sex and with well-defined exclusion criteria, (2) the use 
of an anatomically shaped femoral stem with expected minor 
stress-shielding effects on the proximal femur, (3) the use of 
ceramic-ceramic weight-bearing surfaces, and (4) the statisti-
cal assessment of many potential patient-related factors. The 
use of ceramic-ceramic bearing surfaces was expected to min-
imize generation of wear particles as a potential cause of peri-
prosthetic bone resorption, although a recent study showed no 
difference in periprosthetic bone loss in patients with ceramic-
ceramic articulations as opposed to ceramic-on-polyethylene 
articulations (Kim et al. 2007). Our study did not address the 
possible impact of sex, type of cementless stem, or cement 
fixation on the degree of periprosthetic bone loss. There have 
been reports using quantitative computed tomography (CT) 
to measure BMD around prosthetic components (Mueller et 
al. 2007). The CT technique allows a true 3-dimensional den-
sitometry with high precision. Compared to the conventional 
DXA used in this study, quantitative CT would certainly bring 
new insights into the remodeling processes. 
JJA and TJM collected and analyzed the data and prepared the manuscript, 
PL performed DXA measurements, NM performed morphometric analyses 
of the radiographs, TV performed the statistical analyses, and HTA designed 
and organized the study. 
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